Balinatunfib(口服TNFR1信号抑制剂)治疗轻中度银屑病的1期研究
本研究为1期、4周、随机、双盲、安慰剂对照试点研究,纳入38例18-65岁慢性斑块型银屑病且PASI≤16、至少2个皮损TLSS≥4的男性患者,随机接受200mg balinatunfib(N=26)或安慰剂(N=12)。结果显示无严重或重度TEAE,味觉障碍(61.5% vs 0%)和恶心(19.2% vs 0%)最常见;第2周和第4周TLSS较基线改善优于安慰剂(17.06% vs 6.29%,p=0.032;38.18% vs 20.44%,p=0.012)。
要点
- Balinatunfib 200mg口服4周在轻中度银屑病中未观察到严重或重度TEAE。
- 味觉障碍和恶心是最常见的治疗中出现的不良事件。
- 第2周和第4周TLSS改善显著优于安慰剂,PASI和血清IL-22、IL-17F也呈改善趋势。
核心结论
- Balinatunfib在轻中度银屑病患者中未报告严重或重度TEAE,并显示出有前景的临床应答,支持进一步评估TNFR1信号抑制在炎症性疾病中的作用。
研究设计与样本
- 1期、4周、随机、双盲、安慰剂对照试点研究,在德国单中心纳入38例18-65岁慢性斑块型银屑病男性患者。
- 纳入标准为PASI≤16且筛选期和基线时至少2个皮损的TLSS≥4。
- 患者随机接受200mg balinatunfib(N=26)或安慰剂(N=12)。
- 主要终点为不良事件(AEs)、治疗中出现的不良事件(TEAEs)和特别关注的不良事件的发生率。
主要发现
- 研究期间未观察到严重或重度TEAE或特别关注的不良事件。
- Balinatunfib组与安慰剂组最常见的TEAE为味觉障碍(61.5% vs 0%)和恶心(19.2% vs 0%)。
- 第2周TLSS较基线改善:balinatunfib组17.06% vs 安慰剂组6.29%(p=0.032)。
- 第4周TLSS较基线改善:balinatunfib组38.18% vs 安慰剂组20.44%(p=0.012)。
- 探索性分析提示第2周总PASI改善17.73% vs 4.12%(nominal p=0.005),第4周35.09% vs 15.71%(nominal p=0.009),并降低血清IL-22(nominal p=0.0001)和IL-17F(nominal p=0.0025)水平。
关键数值与推荐
- 主要终点安全性:未观察到严重或重度TEAE或特别关注的不良事件。
- 次要终点TLSS第2周改善17.06% vs 6.29%(p=0.032),第4周改善38.18% vs 20.44%(p=0.012)。
- 探索性终点总PASI第2周改善17.73% vs 4.12%(nominal p=0.005),第4周35.09% vs 15.71%(nominal p=0.009)。
- 血清IL-22下降nominal p=0.0001,IL-17F下降nominal p=0.0025。
临床怎么用
- Balinatunfib作为首个口服选择性TNFR1信号抑制剂,在轻中度银屑病中显示出可接受的安全性和初步临床应答。
- 味觉障碍和恶心是需关注的不良事件,用药期间应监测。
- 目前仅为1期4周试点研究,尚不能用于临床常规治疗决策。
局限性
- 本研究为1期、4周、单中心、小样本试点研究,仅纳入男性患者。
- PASI和血清生物标志物结果为探索性分析,使用nominal p值,未校正多重比较。
- 研究仅纳入轻中度银屑病患者,结论不能外推至重度患者或其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activation of tumour necrosis factor receptor 1 (TNFR1) promotes inflammation in several autoimmune diseases. OBJECTIVES: To evaluate safety, tolerability and clinical efficacy of balinatunfib versus placebo in patients with mild-to-moderate psoriasis. METHODS: Phase-1, 4-week, randomized, double-blind, placebo-controlled pilot study, including patients aged 18-65 years with chronic plaque-type psoriasis with mild-to-moderate severity as defined by Psoriasis Area Severity Index (PASI ≤16) and ≥2 lesions with a Target Lesion Severity Score (TLSS) ≥4 at both screening and baseline. The primary endpoint was safety and tolerability of balinatunfib as assessed by the incidence of adverse events (AEs), treatment-emergent AEs (TEAEs) and AEs of special interest. Secondary endpoints were the percent change in TLSS from baseline to Weeks 2 and 4. Serum biomarkers, interleukin-22 (IL-22), IL-17F and percent change in PASI from baseline to Weeks 2 and 4, were also evaluated. RESULTS: 38 male patients (age [mean ± SD], 43 ± 10.6) were randomized to receive 200-mg balinatunfib (N = 26) or placebo (N = 12). No serious or severe TEAEs or adverse events of special interest were observed during the study. Dysgeusia (61.5% vs. 0%) and nausea (19.2% vs. 0%) were the most frequently reported TEAEs in the balinatunfib versus the placebo groups. Balinatunfib showed improvements from baseline in TLSS vs. placebo at Week 2 (17.06% vs. 6.29%, p = 0.032) and Week 4 (38.18% vs. 20.44%, p = 0.012). Exploratory analyses suggested an improvement in the total PASI scores at Week 2 (17.73% vs. 4.12%, nominal p = 0.005), Week 4 (35.09% vs. 15.71%, nominal p = 0.009) and decreased serum levels of IL-22 (nominal p = 0.0001) and IL-17F (nominal p = 0.0025) with balinatunfib treatment. CONCLUSIONS: Patients with mild-to-moderate psoriasis treated with balinatunfib reported no severe or serious TEAEs and showed promising clinical responses, suggesting that further evaluation of TNFR1 signal inhibition in inflammatory diseases is warranted. Psoriasis, a skin condition characterized by the formation of red or silver coloured patches on the surface of the skin, affects 2%–3% of the population worldwide. Mechanistic studies of psoriasis have shown that tumour necrosis factor (TNF), a protein that elicits inflammation and is produced by different blood cells, plays an important role in the development of disease. TNF transmits its signals through ‘cellular antennae’s’ or receptors (TNFR1 and TNFR2) that receive TNF signal and initiate different cellular responses. TNFR1‐initiated cellular responses are largely deleterious and promote disease, whereas TNFR2‐initiated cellular responses are largely reported to be protective in nature, promoting tissue repair. One of the current treatment options for psoriasis includes medicines (given as injections) that target TNF. These medicines inhibit both TNFR1‐ and TNFR2‐ mediated cellular responses. Balinatunfib is a medicine that is being developed as a potential new treatment for patients with psoriasis and other inflammatory diseases. Balinatunfib is the first oral medicine that selectively inhibits TNFR1 signalling to potentially stop or slow the disease‐causing processes, while preserving signals initiated through TNFR2. The aim of this proof‐of‐mechanism, 4‐week pilot study was to examine safety, tolerability and clinical response of balinatunfib in patients with mild‐to‐moderate psoriasis. The study enrolled 38 participants from a single site in Germany. We found that the patients responded well to the treatment with no serious undesirable treatment effects. Additionally, the patients showed reduced disease severity after treatment compared to patients that received sham treatment. These results support the continued development of balinatunfib as a potential oral treatment in inflammatory diseases.
引用
- Nassr N, Chow OA, Nguyen MA, et al. Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol. 2026. PMID: 41671079. doi:10.1111/jdv.70262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。